HopeCare Global
Closing the gap

New Federal Developments May Shape Ovarian Cancer Treatment and Women’s Preventive Care

4 min readNovember 9, 2026

HopeCare Global is closely monitoring two new federal developments. The U.S. Food and Drug Administration has scheduled a public workshop focused specifically on ovarian cancer maintenance treatment, while the Health Resources and Services Administration has opened a $1 million funding opportunity to strengthen women’s preventive services guidelines.

These actions do not establish a new ovarian cancer screening test, approve a new ovarian cancer drug or create final regulatory guidance. They do, however, open important discussions about how emerging treatments should be evaluated and how women’s preventive services should be reviewed, communicated and delivered.

FDA Workshop on Ovarian Cancer Maintenance Treatment

The FDA Oncology Center of Excellence will hold a two-session virtual public workshop titled Maintenance Treatment for Ovarian Cancer Workshop: Weighing Benefit and Toxicity in an Evolving Landscape. The sessions will take place on November 12 and November 19, 2026, from 12:30 p.m. to 4:30 p.m. Eastern Time.

The FDA states that new products, including antibody-drug conjugates, are being investigated as maintenance treatments for ovarian cancer and that some of these therapies may carry substantial toxicity. Maintenance treatment is intended to delay recurrence or progression after initial treatment, but the benefits must be weighed against adverse effects, treatment burden and long-term outcomes.

The workshop will examine several issues that can influence future clinical trials, regulatory decisions and product labeling:

  • Whether progression-free survival reflects a clinically meaningful benefit for patients
  • How overall survival should be incorporated into trial design and how potential survival harm should be monitored
  • How safety, toxicity and dosing should affect regulatory decisions, labeling and clinical use
  • How predictive biomarkers should be integrated into ovarian cancer trials
  • What benefit-risk standards emerging maintenance treatments should meet

Why the FDA Discussion Matters

For patients and families, a longer period without disease progression is important, but it is not the only meaningful outcome. Treatment decisions should also consider overall survival, quality of life, cumulative toxicity, financial burden and the ability to continue daily activities.

HopeCare Global also believes ovarian cancer trials must include women from populations that have historically been underrepresented in research. Black women, rural residents, older adults, immigrants and women receiving care in medically underserved communities should be represented so that benefit-risk decisions reflect the people who will use these treatments.

As treatment becomes increasingly driven by biomarkers, equitable access to genomic testing, specialty care and clear patient education must remain part of the regulatory conversation. Patients should understand the difference between delaying progression, improving quality of life and demonstrating longer survival.

HRSA Funding for Women’s Preventive Care

On November 6, 2026, the U.S. Department of Health and Human Services, through HRSA, announced the Women’s Initiative for Screening and Health. The WISH program will provide one cooperative agreement of up to $1 million in fiscal year 2027 to establish a multidisciplinary coalition that will review evidence, recommend updates to the HRSA-supported Women’s Preventive Services Guidelines and improve the use of those guidelines in clinical practice.

The selected organization must convene a panel of at least 10 experts representing women’s health, primary care, public health, preventive medicine, behavioral health, patient and consumer organizations and organizations serving medically underserved women. The program will also support the development and dissemination of information for communities with limited resources.

Eligible applicants include nonprofit organizations with or without federal tax-exempt status, institutions of higher education, government entities and businesses. Applications are due January 8, 2027, at 11:59 p.m. Eastern Time under opportunity number HRSA-27-072.

Why the WISH Program Matters

HRSA-supported preventive services guidelines can influence both clinical practice and insurance coverage. Federal law generally requires non-grandfathered group health plans and individual insurance coverage to cover HRSA-supported preventive services without copayments, deductibles or coinsurance.

The new funding opportunity does not specifically establish ovarian cancer screening, and there is still no reliable screening test for ovarian cancer in women who do not have symptoms. HopeCare Global will continue to protect that distinction. Ovarian cancer symptom awareness and tracking are not the same as population screening or diagnosis.

The WISH initiative nevertheless creates an opening for community organizations to advocate for stronger education about hereditary ovarian cancer risk, access to genetic counseling and testing, timely evaluation of persistent ovarian cancer symptoms and appropriate referral to gynecologic oncology. These priorities are especially important for women in rural and medically underserved communities.

HopeCare Global’s Advocacy Priorities

HopeCare Global will continue urging federal agencies, researchers, professional organizations and healthcare partners to:

  • Include ovarian and other gynecologic cancers explicitly in federal women’s health initiatives
  • Evaluate treatment benefits alongside survival, toxicity, quality of life and patient-reported outcomes
  • Improve access to hereditary-risk assessment, genetic counseling, genomic testing and gynecologic oncology
  • Include Black, immigrant, rural, older and medically underserved women in research and implementation efforts
  • Partner with community organizations to provide culturally and linguistically appropriate education

Ovarian Cancer Symptom Awareness

Because there is no reliable general-population screening test for ovarian cancer, knowing and tracking persistent symptoms remains important. HopeCare Global developed OvaTrack to support ovarian cancer symptom awareness and help users prepare for conversations with healthcare professionals. OvaTrack is an educational symptom-tracking resource. It is not a screening or diagnostic tool and does not replace professional medical evaluation.

Know the Signs. Track Symptoms. Act Early.